Loss of Striatal [76Br]Bromospiperone Binding Sites Demonstrated by Positron Tomography in Progressive Supranuclear Palsy
暂无分享,去创建一个
Y. Agid | A. Bonnet | J. Baron | H. Cambon | B. Maziére | Y. Agid | J. C. Baron | C. Loc'h | B. Mazière | H. Cambon | P. Sgouropoulos | A. M. Bonnet | P. Sgouropoulos | C. Loc'h | Jean-Claude Baron | Bernard Maziere | Yves Agid | Bernard Mazière | Jean-Claude Baron
[1] D Comar,et al. Crossed cerebellar diaschisis. Further studies. , 1986, Brain : a journal of neurology.
[2] E. Hirsch,et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy , 1985, Annals of neurology.
[3] S. Luthra,et al. NEW LABELLED LIGAND FOR IN-VIVO STUDIES OF OPIOID PHYSIOLOGY , 1985, The Lancet.
[4] J. Baron,et al. In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [76Br]bromospiperone. , 1985, European journal of pharmacology.
[5] T Greitz,et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[6] Y. Agid,et al. PROGRESSIVE SUPRANUCLEAR PALSY: LOSS OF STRIATAL DOPAMINE RECEPTORS DEMONSTRATED IN VIVO BY POSITRON TOMOGRAPHY , 1985, The Lancet.
[7] J. Mazziotta,et al. Positron emission tomography: human brain function and biochemistry. , 1985, Science.
[8] J S Fowler,et al. [18F]-N-Methylspiroperidol: the radioligand of choice for PETT studies of the dopamine receptor in human brain. , 1985, Life sciences.
[9] D Comar,et al. Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. , 1985, European journal of pharmacology.
[10] C. D. Arnett,et al. Comparison of Three 18F‐Labeled Butyrophenone Neuroleptic Drugs in the Baboon Using Positron Emission Tomography , 1985, Journal of neurochemistry.
[11] Dean F. Wong,et al. Imaging Opiate Receptors in the Human Brain by Positron Tomography , 1985, Journal of computer assisted tomography.
[12] Dopaminergic receptor sites in human brain , 1985, Neurology.
[13] G. di Chiro,et al. Atlas of Dopamine Receptor Images (PET) of the Human Brain , 1985, Journal of computer assisted tomography.
[14] D Comar,et al. Muscarinic cholinergic receptor in the human heart evidenced under physiological conditions by positron emission tomography. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[15] M. Folstein,et al. EFFECTS OF AGE ON DOPAMINE AND SEROTONIN RECEPTORS MEASURED BY POSITRON TOMOGRAPHY IN THE LIVING HUMAN BRAIN , 1984, Science.
[16] A. Wolf,et al. Mapping brain neuroleptic receptors in the live baboon. , 1984, Biological psychiatry.
[17] R. Naquet,et al. 76Br-bromospiroperidol: a new tool for quantitative in-vivo imaging of neuroleptic receptors. , 1984, Life sciences.
[18] L. C. Murrin,et al. Dopamine Receptors: Effects of Chronic L‐Dopa and Bromocriptine Treatment in an Animal Model of Parkinson's Disease , 1984, Clinical neuropharmacology.
[19] A. Syrota,et al. Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography. , 1984, Life sciences.
[20] D. Brooks,et al. PRE-SYNAPTIC AND POST-SYNAPTIC DOPAMINERGIC SYSTEM IN HUMAN BRAIN , 1984, The Lancet.
[21] Y. Agid,et al. [3H]spiperone binding in the nigrostriatal system in human brain. , 1984, European journal of pharmacology.
[22] Y Agid,et al. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. , 1984, European journal of pharmacology.
[23] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[24] F. Soussaline,et al. Physical characterization of a time-of-flight positron emission tomography system for whole-body quantitative studies , 1984 .
[25] O. DeJesus,et al. Measurements in vivo of parameters of the dopamine system , 1984, Annals of neurology.
[26] M. Mintun,et al. Comparison in animal models of 18F-spiroperidol and 18F-haloperidol: potential agents for imaging the dopamine receptor. , 1983, Life sciences.
[27] T. Crow,et al. DOPAMINE RECEPTORS DISPLAYED IN LIVING HUMAN BRAIN WITH 77Br-p-BROMOSPIPERONE , 1983, The Lancet.
[28] Jonathan M. Links,et al. Imaging dopamine receptors in the human brain by positron tomography , 1983 .
[29] T. Crow,et al. 77Br-p-bromospiperone: a ligand for in vivo labelling of dopamine receptors. , 1983, Life sciences.
[30] J. C. Stoof. Dopamine Receptors in the Neostriatum: Biochemical and Physiological Studies , 1983 .
[31] C. D. Arnett,et al. Specific Binding of [11C]Spiroperidol in Rat Brain In Vivo , 1983, Journal of neurochemistry.
[32] T. Ban,et al. Central nervous system receptors in neuropsychiatric disorders , 1982, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[33] J. Marcusson,et al. Age‐Correlated Loss of Dopaminergic Binding Sites in Human Basal Ganglia , 1982, Journal of neurochemistry.
[34] J. Mazziotta,et al. TOMOGRAPHIC MAPPING OF HUMAN CEREBRAL METABOLISM: NORMAL UNSTIMULATED STATE , 1981 .
[35] J. Mazziotta,et al. Tomographic mapping of human cerebral metabolism , 1981, Neurology.
[36] H. K. Kulmala,et al. Specific in vivo binding of 77Br-p-bromospiroperidol in rat brain: a potential tool for gamma ray imaging. , 1981, Life sciences.
[37] H. Meltzer,et al. Synthesis and biological evaluation of p-bromospiperone as potential neuroleptic drug. , 1980, Journal of pharmaceutical sciences.
[38] M E Phelps,et al. Positron emission tomography. , 1979, Medical instrumentation.
[39] J. Leysen,et al. Spiperone: a ligand of choice for neuroleptic receptors. 2. Regional distribution and in vivo displacement of neuroleptic drugs. , 1978, Biochemical pharmacology.
[40] A. Herz,et al. The demonstration in vivo of specific binding sites for neuroleptic drugs in mouse brain , 1977, Brain Research.
[41] J. Steele. Progressive supranuclear palsy. , 1972, Brain : a journal of neurology.